Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Intravitreal MHU650 in Macular Edema
NCT04635800Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of MHU650 in diabetic macular edema (DME), neovascular age-related macular degeneration (NVAMD) and retinal vein occlusion (RVO) (4 cohorts), sponsored by Novartis. Primary endpoints: Number of participants with ocular and nonocular adverse events, Change from baseline in Best Correct Visual Acuity and 2 more. Started Dec 2020; status: completed.
02
Drugs
MHU650
03
Conditions
diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT04635800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635800.